FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Panel to Review Pulse Oximeter Accuracy

Federal Register Notice: FDA announces an 11/1 Advisory Committee meeting to discuss ongoing concerns that pulse oximeters may be less accurate in cer...

latest-news-card-1
FDA General

FDA Challenges Illicit Trade Workshop Attendees

FDA associate commissioner Mark Abdoo calls for greater collaborative efforts worldwide to combat illicit trade in healthcare products.

latest-news-card-1
Medical Devices

Baxter Clearlink Solution Set Recall is Class 1

FDA says Baxter Healthcares recall of its Clearlink Basic Solution Sets with Duovent is Class 1.

latest-news-card-1
Federal Register

Regulatory Review Period for Caplyta

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Intra-Cellular Therapies Caplyta.

latest-news-card-1
Medical Devices

Advisors to Discuss Pulse Oximeter Accuracy

FDA says the Anesthesiology and Respiratory Therapy Devices Panel will meet virtually on 11/1 to discuss issues of potential pulse oximeter inaccuracy...

latest-news-card-1
Human Drugs

Elemental Impurities Guidance

FDA publishes an International Conference on Harmonization revised guidance on elemental impurities in drug products.

latest-news-card-1
Federal Register

Tavalisses Regulatory Review Period Determined

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Rigel Pharmaceuticals Tavalisse.

latest-news-card-1
Human Drugs

FDA Investigators Target Pharmaceutical Water Systems

CDER Office of Manufacturing Quality director Francis Godwin warns that FDA investigators are paying close attention to pharmaceutical water systems d...

latest-news-card-1
Human Drugs

FDA Approves Mallinckrodt Kidney Drug

FDA approves Mallinckrodts Terlivaz (terlipressin) injection for improving kidney function in certain adults with hepatorenal syndrome.

latest-news-card-1
Federal Register

Regulatory Review Period for Bulkamid

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Conturas Bulkamid Urethral Bulking System.